Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Population pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014
Impact of candida spp. colonization of respiratory tract in patients with intensive care unit-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015
Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014
Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002
Evaluation of antibiotics therapy for low respiratory tract infections Source: Eur Respir J 2007; 30: Suppl. 51, 406s Year: 2007
Persistence of staphylococcus aureus in lower respiratory tract in patients undergoing mechanical ventilation Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229 Year: 2004
Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014
Treatment of respiratory tract infections: comparison of telithromycin and azithromycin Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues Year: 2015
Fluoroquinolones and lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=94 Year: 2004
Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Antibiotics and new guidelines for the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=175 Year: 2004
Clinical characteristics of chronic pulmonary aspergillosis and colonization; retrospective analysis of patients with isolation of asperguillus species from respiratory samples Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Lower respiratory tract infections: when are antibiotics mandatory? Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146 Year: 2004
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines Source: Eur Respir J 2011; 37: 112-118 Year: 2011